What Is CT-388? Roche's Cleaner Incretin Story Explained
CT-388 is one of Roche's most important obesity assets and one of the cleaner incretin stories in the mid-stage field. It matters because it gives Roche a plausible lead asset in a category where credibility is still being assembled.
Why this matters
People search this because CT-388 is one of the names that makes Roche's obesity strategy feel real instead of purely aspirational.
Current read
CT-388 is still Roche's cleanest obesity asset to explain. The next step is proving it can mature from a credible mid-stage story into a genuine threat rather than a respectable supporting asset.
Primary query
what is ct-388
Page type
Pipeline Theme
Lead read
CT-388
Stage mix
2 phase 2 · 1 phase 3
Pipeline facts for search and AI answers
What this pipeline theme page answers
Primary query
what is ct-388
The page is built to answer this pipeline query directly before routing readers deeper.
Tracker type
Pipeline Theme
This page answers a focused pipeline question and connects it to the compounds, timelines, and comparisons that matter most.
Lead read
CT-388
CT-388 is still Roche's cleanest obesity asset to explain. The next step is proving it can mature from a credible mid-stage story into a genuine threat rather than a respectable supporting asset.
Stage mix
2 phase 2 · 1 phase 3
FormBlends separates early pipeline interest from late-stage, filed, and approved assets.
Direct answer
What is it?
CT-388 is a phase 2 program from Roche/Carmot built around GLP-1/GIP.
Why does it matter?
CT-388 is one of Roche's most important obesity assets and one of the cleaner incretin stories in the mid-stage field. It matters because it gives Roche a plausible lead asset in a category where credibility is still being assembled.
What should you read next?
What we know right now
CT-388 is one of Roche's most important obesity assets and one of the cleaner incretin stories in the mid-stage field. It matters because it gives Roche a plausible lead asset in a category where credibility is still being assembled.
CT-388 is still Roche's cleanest obesity asset to explain. The next step is proving it can mature from a credible mid-stage story into a genuine threat rather than a respectable supporting asset.
Right now this page is anchored by CT-388, VK2735, Petrelintide, which is why the lane feels more concrete than a generic trend piece.
What is still uncertain
This topic includes at least one late-stage asset, which means the lane is more than conceptual. The open question is usually positioning, timing, and differentiation.
The next milestone is decisive late-stage readouts and filing discipline. At this stage, weak differentiation can matter as much as efficacy.
The biggest mistake in obesity pipeline content is treating strategic interest like commercial inevitability. This page is built to keep those two things separate.
What FormBlends is watching
- Whether Roche keeps CT-388 at the center of its obesity narrative
- How it compares with other mid-stage leaders on clarity and momentum
- Whether the asset starts to feel like a true top-tier program
Decision path
How should I interpret What Is CT-388? Roche's Cleaner Incretin Story Explained?
This pipeline page is a decision aid for market context, not a patient access page. Use it to understand which mechanisms, companies, and trial stages are worth watching before comparing anything to available care.
- Topic
- what is ct-388
- Type
- Pipeline Theme
- Tracked names
- 3
- Stage mix
- 2 phase 2 · 1 phase 3
Step 1
Check maturity
This topic includes at least one late-stage asset, which means the lane is more than conceptual. The open question is usually positioning, timing, and differentiation.
Step 2
Watch the next signal
The next milestone is decisive late-stage readouts and filing discipline. At this stage, weak differentiation can matter as much as efficacy.
Open status hubStep 3
Compare to care today
Pipeline excitement should be separated from treatment decisions that require provider review, a legally available medication, and follow-up.
View current optionsHow this lane stacks up right now
A quick read on the compounds carrying the most weight on this page.
| Compound | Developer | Mechanism | Stage | Next step |
|---|---|---|---|---|
| CT-388 | Roche/Carmot | GLP-1/GIP | Phase 2 | Read status page |
| VK2735 | Viking Therapeutics | GLP-1/GIP | Phase 3 | Read status page |
| Petrelintide | Roche/Zealand | Amylin | Phase 2 | Read status page |
Featured compounds in this lane
These are the names currently doing the real work in this part of the pipeline.
Related comparisons
CT-388 vs VK2735: Roche's Dual Agonist Entry vs Viking's Lead Asset
VK2735 is ahead. CT-388 is still more of a watchlist asset than a category-defining one. That can change, but today this is mainly a comparison between a late-stage contender and a promising chaser.
Roche vs Viking Obesity Pipeline: Big-Pharma Depth vs Independent Focus
Roche has the broader and safer obesity platform. Viking has the more concentrated and strategically explosive one. If you want depth, Roche wins. If you want a pure upside challenger story, Viking is more interesting.
FormBlends separates trial-stage tracking from actual patient availability.
Late-stage, filed, and approved assets are treated differently from early exploratory programs.
This page is meant to answer the query fast, then route readers into compound, status, and comparison pages for deeper analysis.